Guangzhou Innogen Pharmaceutical Group (2591) H2 2025 earnings summary

Executive summary

• 2025 marked a shift toward parallel R&D and commercialisation; Efsubaglutide Alfa was approved and launched for T2D in China, with Macau launch in September.

• Included in China’s NRDL for adult T2D from 1 January 2026; the product was also added to the 2025 primary-care diabetes guidelines.

Financial highlights

• Revenue was RMB131.5m, primarily from Efsubaglutide Alfa sales in China; gross profit was RMB117.1m.

• Net loss widened to RMB341.4m from RMB174.7m in 2024, reflecting sharply higher R&D and selling and distribution expenses.

• R&D expense rose to RMB205.8m from RMB102.5m; selling and distribution expense increased to RMB176.6m from RMB2.4m.

• Administrative expense declined to RMB77.4m from RMB84.5m; other income and gains fell to RMB13.7m from RMB20.1m.

• Basic and diluted loss per share was RMB0.79, versus RMB0.42 in 2024.

Outlook and guidance

• 2026 priorities include expanding hospital access, channel coverage and academic promotion for T2D, supported by NRDL inclusion and a larger commercial team.

• Hong Kong launch preparations are planned for 2026; weight-management pre-launch planning is conditional on Phase III results and regulatory progress.

• China obesity/overweight Phase III topline data is expected by end-2026; the Australia Phase II study is expected to complete in 2026.

• T1D and AD programs are in IND-enabling stages and expected to progress toward IND submissions in 2026, subject to development progress.

• Overseas registration and selective commercialisation plans cover Hong Kong, Southeast Asia, Latin America and other selected markets.